QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

23,200 signal articles · 358 in last 24h · 110,866 total before filter · latest 1h ago
358last 24h
2357last 7d
425● bullish (7d)
221● bearish (7d)
202publishers
AllMacro263Earnings1423M&A99Regulatory17Product16Analyst22
✕ clear all filtersticker: UNHSentiment:bullishneutralbearishshow all (incl. clickbait)
Healthcare Investing Is Now an AI Short in Disguise
The Wall Street Journal21h agoneutral
Healthcare Investing Is Now an AI Short in Disguise

For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.

CVS Health Q2 Earnings Call Highlights
MarketBeat5d agoneutral
CVS Health Q2 Earnings Call Highlights

CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow. Chair and Chief Executive Officer David Joyner said the company gener

Bloomberg6d agobearish
CVS Falls After Preliminary 2027 Guidance Disappoints

(Bloomberg) -- CVS Health Corp. shares fell after the company gave preliminary 2027 profit guidance that disappointed investors and warned of challenges in its pharmacy benefit manager next year, overshadowing a better-than-expected second quarter report.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasi

CVS Stock Rises Near Buy Point On Hearty Earnings Checkup
Investor's Business Daily6d agobullish
CVS Stock Rises Near Buy Point On Hearty Earnings Checkup

CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.

Guardant Health Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Guardant Health Q2 Earnings Call Highlights

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses. The company also raised its full-year revenue outlook, citing demand for its Guardant360 and Shield o

Humana Q2 Earnings Call Highlights
MarketBeat13d agoneutral
Humana Q2 Earnings Call Highlights

Humana (NYSE:HUM) said its 2026 performance is tracking in line with expectations, with management emphasizing planned Medicare Advantage margin expansion in 2027, progress in its Stars program and continued operating-cost reductions as key components of its path toward a sustainable pretax margin o

ENI Q2 Earnings Call Highlights
MarketBeat13d agoneutral
ENI Q2 Earnings Call Highlights

ENI (NYSE:E) reported sharply higher second-quarter and first-half results, citing upstream production growth, favorable market conditions and stronger contributions from its gas, low-carbon and refining-related businesses. Chief Executive Officer Claudio Descalzi said second-quarter pro forma EBIT

Humana Stock Stumbles After Earnings Underwhelm
The Wall Street Journal13d agobearish
Humana Stock Stumbles After Earnings Underwhelm

Humana’s shares dipped in morning trading after its results compared unfavorably with other insurers’ performance this quarter The Medicare-focused insurer modestly beat analysts’ profit projections, offered reassurance on medical cost trends and left guidance unchanged on an adjusted basis.

Medicare Drug Plan Premiums Are About to Jump for 25 Million Seniors
Barrons.com13d agobullish
Medicare Drug Plan Premiums Are About to Jump for 25 Million Seniors

Medicare beneficiaries may face higher premiums next year for their Part D drug plans, as the federal government plans to end subsidies that helped mitigate price increases in the program. The Trump administration will not continue the subsidies beyond 2026, The Wall Street Journal reported. About 25 million Medicare recipients are enrolled in a stand-alone Part D plan for their drug coverage.

Why Prices Could Rise for Medicare Drug Plans Next Year
Barrons.com14d agoneutral
Why Prices Could Rise for Medicare Drug Plans Next Year

Medicare beneficiaries may face higher premiums next year for their Part D drug plans, as the federal government plans to end subsidies that helped mitigate price increases in the program. The Trump administration will not continue the subsidies beyond 2026, The Wall Street Journal reported. About 25 million Medicare recipients are enrolled in a stand-alone Part D plan for their drug coverage.

UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
TheStreet19d agoneutral
UnitedHealth’s earnings comeback hides a risk Wall Street can’t price

UnitedHealth Group (UNH) just delivered the quarter battered shareholders have been waiting for. The health care company blew past Wall Street's profit prediction, increased its most widely monitored cost index, and boosted its full-year earnings outlook. The results seemed to vindicate investors ...

UnitedHealth CFO sends stark warning after earnings
TheStreet23d agoneutral
UnitedHealth CFO sends stark warning after earnings

UnitedHealth Group (UNH) beat Wall Street's numbers on July 16, 2026, but its chief financial officer spent the earnings call making sure nobody mistook that result for a solved cost problem. The company beat earnings estimates by roughly 30%, and management raised full-year guidance well past ...

Bloomberg25d agoneutral
Circle Gets Street-Low Target as Stablecoin Competition Heats Up

(Bloomberg) -- Circle Internet Group Inc. shares have lost more than three-quarters of their value from the highs seen just after their initial public offering last year and as more stablecoins come to market, one analyst is warning it could get worse.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthCIA Says AI Drones Give Russian T